Peresolimab - Eli Lilly and Company
Alternative Names: LY-3462817Latest Information Update: 22 Jul 2024
At a glance
- Originator Eli Lilly and Company
- Class Antipsoriatics; Antirheumatics; Monoclonal antibodies
- Mechanism of Action Programmed cell death 1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Rheumatoid arthritis
- No development reported Plaque psoriasis
Most Recent Events
- 12 Jun 2024 Pharmacodynamics data from phase II clinical trials in Rheumatoid arthritis presented at the 25th Annual Congress of the European League Against Rheumatism (EULAR-2024)
- 11 Jan 2024 Eli Lily and Company completes a phase I safety and pharmacokinetics trial (In volunteers) in USA (SC) (NCT05959109)
- 21 Jul 2023 Eli Lilly and Company initiates enrolment in a phase I trial (In volunteers) in USA (SC) (NCT05959109)